SUGT1P1: A Protein Targeted for Cancer, Autoimmune & Infectious Diseases

Target Name: SUGT1P1

NCBI ID: G441394

SUGT1P1

Other Name(s): SUGT1P | SUGT1 pseudogene 1 | SGT1P | bA255A11.1

SUGT1P1: A Protein Targeted for Cancer, Autoimmune & Infectious Diseases

SUGT1P1, also known as SUGT1P, is a protein that is expressed in many tissues throughout the body. It is a key regulator of cell signaling, particularly in the T cells, which play a crucial role in the immune system.SUGT1P1 has been identified as a potential drug target and is currently being targeted by researchers to develop new treatments for various diseases.

The SUGT1P1 protein is composed of 256 amino acids and has a calculated molecular weight of 31 kDa. It is located in the cytoplasm and is associated with the T-cell receptor alpha chain.SUGT1P1 is a glycoprotein, which means it consists of a protein that is covalently bound to a glycine molecule.

SUGT1P1 is a post-transcriptionally modified protein, that is, some sugar-modified modifications are added during the post-transcriptional modification process. These modifications can affect the structure, function and stability of proteins, thereby affecting the physiological activities of cells.

Under normal circumstances, SUGT1P1 is a protein encoded by the gene. These genes can be expressed in many different tissues and organs, including nervous tissue, immune system, urinary system, cardiovascular system, etc. SUGT1P1 plays an important role in cell signaling.

The role of SUGT1P1 in cell signaling is mainly reflected in regulating the activation process of T cell receptor (TCR). TCR is a membrane protein that plays an important role in the interaction between cells and the external environment. After TCR is activated, it can bind to MHC molecules presented by antigen-presenting cells (APC), thereby activating the cell cycle and immune response of T cells.

Studies have shown that SUGT1P1 plays an important role in regulating TCR activation. In addition, it can affect the activity of other intracellular signaling molecules, including phosphatidylinositol (PI) and kinases in the FAK/AKT signaling pathway.

Because SUGT1P1 plays an important role in cell signaling, it is considered a potential drug target. Currently, researchers are exploring the role of SUGT1P1 in treating various diseases, including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.

In cancer treatment, SUGT1P1 is considered a potential drug target. Studies have shown that the expression level of SUGT1P1 is closely related to the prognosis and treatment response of various cancers. For example, patients with higher levels of SUGT1P1 expression tend to have worse survival rates and poorer treatment responses. Therefore, researchers are exploring whether SUGT1P1 inhibitors can serve as a new cancer treatment strategy.

In autoimmune diseases, SUGT1P1 is also considered a potential drug target. Autoimmune diseases are diseases in which the immune system mistakenly attacks its own tissues or organs, such as diabetes, rheumatoid arthritis, and autoimmune hepatitis. Studies have shown that SUGT1P1 is increasingly associated with a variety of autoimmune diseases, and the inhibition of SUGT1P1 may also be a new therapeutic strategy.

In inflammatory and infectious diseases, SUGT1P1 is also considered a potential drug target. These diseases are often caused by inflammation or infection, such as gingivitis, oral infections and inflammatory bowel disease. Studies have shown that the expression level of SUGT1P1 in these diseases is closely related to disease severity and treatment response. Therefore, researchers are exploring whether SUGT1P1 inhibitors can serve as a new therapeutic strategy.

SUGT1P1 is a protein that plays an important role in cell signaling. Currently, researchers are exploring the role of SUGT1P1 in treating various diseases, including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases. Inhibition of SUGT1P1 may be a new drug target and provide new strategies for the treatment of these diseases.

Protein Name: SUGT1 Pseudogene 1

The "SUGT1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUGT1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets